tiprankstipranks
Advertisement
Advertisement

SGIOF Stock Latest News

Shionogi Extends Pompe Program: What S-606001’s New Phase 2 Study Means for SGIOF Investors
Company AnnouncementsShionogi Extends Pompe Program: What S-606001’s New Phase 2 Study Means for SGIOF Investors
3d ago
SGIOF
Shionogi Advances Phase 3 Secutrelvir Trial, Eyeing New COVID-19 Market Upside
PremiumCompany Announcements
Shionogi Advances Phase 3 Secutrelvir Trial, Eyeing New COVID-19 Market Upside
4d ago
SGIOF
Shionogi’s Q1 Earnings Surge on Acquisitions, HIV Royalties and Overseas Growth
PremiumCompany Announcements
Shionogi’s Q1 Earnings Surge on Acquisitions, HIV Royalties and Overseas Growth
7d ago
Shionogi’s Q1 FY2026 Profit Surges on Strong Revenue Growth, Full-Year Guidance Intact
PremiumCompany Announcements
Shionogi’s Q1 FY2026 Profit Surges on Strong Revenue Growth, Full-Year Guidance Intact
7d ago
SGIOF Earnings this Week: How Will it Perform?
PremiumPre-Earnings
SGIOF Earnings this Week: How Will it Perform?
8d ago
Shionogi’s Redasemtide Stroke Trial Completion: What Investors Should Watch Next
PremiumCompany AnnouncementsShionogi’s Redasemtide Stroke Trial Completion: What Investors Should Watch Next
10d ago
SGIOF
Shionogi Targets Pediatric Opioid Side Effects With New Naldemedine Study
Premium
Company Announcements
Shionogi Targets Pediatric Opioid Side Effects With New Naldemedine Study
12d ago
SGIOF
Shionogi Completes Treasury Share Disposal for Restricted Stock Compensation Plan
Premium
Company Announcements
Shionogi Completes Treasury Share Disposal for Restricted Stock Compensation Plan
18d ago
Shionogi to Dispose Treasury Shares for Expanded Restricted Stock Compensation Plan
PremiumCompany Announcements
Shionogi to Dispose Treasury Shares for Expanded Restricted Stock Compensation Plan
2M ago
Shionogi Adopts New Policies to Align Management With Capital Costs and Stock Prices
PremiumCompany Announcements
Shionogi Adopts New Policies to Align Management With Capital Costs and Stock Prices
2M ago
Shionogi Wins Japan Nod for Pediatric Use of COVID-19 Drug XOCOVA
PremiumCompany Announcements
Shionogi Wins Japan Nod for Pediatric Use of COVID-19 Drug XOCOVA
2M ago
Shionogi and F2G Post Positive Phase 3 Results for Novel Antifungal Olorofim
PremiumCompany Announcements
Shionogi and F2G Post Positive Phase 3 Results for Novel Antifungal Olorofim
2M ago
Ueda Boosts Shionogi to Buy, Raising 12‑Month Target to ¥3,400 on Stronger HIV Franchise and Xocova Upside
PremiumRatingsUeda Boosts Shionogi to Buy, Raising 12‑Month Target to ¥3,400 on Stronger HIV Franchise and Xocova Upside
2M ago
Shionogi Wins Early FDA Nod for First Oral Post-Exposure COVID-19 Prophylactic
Premium
Company Announcements
Shionogi Wins Early FDA Nod for First Oral Post-Exposure COVID-19 Prophylactic
2M ago
Shionogi Wins FDA Nod for First Oral COVID-19 Post-Exposure Preventive Drug
Premium
Company Announcements
Shionogi Wins FDA Nod for First Oral COVID-19 Post-Exposure Preventive Drug
2M ago
Shionogi Wins China Approval for Naldemedine to Treat Opioid-Induced Constipation
PremiumCompany Announcements
Shionogi Wins China Approval for Naldemedine to Treat Opioid-Induced Constipation
2M ago
Shionogi Outlines FY2025 Results, FY2026 Outlook and 2030 Strategy
PremiumCompany Announcements
Shionogi Outlines FY2025 Results, FY2026 Outlook and 2030 Strategy
3M ago
Shionogi Lifts FY2025 Earnings and Projects Sharp Revenue Surge for FY2026
PremiumCompany Announcements
Shionogi Lifts FY2025 Earnings and Projects Sharp Revenue Surge for FY2026
3M ago
Shionogi Posts Robust FY2026 Earnings and Projects Strong Growth on Expanded Balance Sheet
PremiumCompany Announcements
Shionogi Posts Robust FY2026 Earnings and Projects Strong Growth on Expanded Balance Sheet
3M ago
Shionogi to Absorb Torii Pharmaceutical in 2027 to Bolster Specialty Drug Business
PremiumCompany AnnouncementsShionogi to Absorb Torii Pharmaceutical in 2027 to Bolster Specialty Drug Business
3M ago
Shionogi Lifts Dividend Forecast on Robust HIV and Infectious Disease Growth
Premium
Company Announcements
Shionogi Lifts Dividend Forecast on Robust HIV and Infectious Disease Growth
3M ago
Shionogi Seals $2.5 Billion RADICAVA Deal to Build Rare Disease Franchise
Premium
Company Announcements
Shionogi Seals $2.5 Billion RADICAVA Deal to Build Rare Disease Franchise
4M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >